Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.

€21.52M EUR

Funder	European Commission
Recipient Organization	Hemispherian As
Country	Norway
Start Date	Jan 01, 2023
End Date	Dec 31, 2025
Duration	1,095 days
Number of Grantees	1
Roles	Coordinator
Data Source	European Commission
Grant ID	`190184696`

Grant Description

Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to treat GBM and all of them provide marginal improvements of